Astria Therapeutics, Inc. (ATXS)
- Business Wire
Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE
BOSTON, February 08, 2023--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced the initiation of the ALPHA-STAR Phase 1b/2 clinical trial of STAR-0215 in people living with HAE. Initial proof-of-concept results in HAE patients from single and multiple dose cohorts are expected in mid-2024.
- Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, February 02, 2023--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 1,800 shares of Astria’s common stock on February 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to indiv
- Business Wire
Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BOSTON, December 19, 2022--Astria Therapeutics, Inc. ("Astria Therapeutics," "Astria," the "Company," "our," or "us") (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced the closing of its previously announced underwritten offering of 10,445,050 shares of its common stock, including the full exercise of the underwriters’ option to
